国际妇产科学杂志

国际妇产科学杂志 ›› 2010, Vol. 37 ›› Issue (5): 299-301.

• 述评 •    下一篇

肿瘤标志物在卵巢癌诊治中的应用

高永良   

  1. 310022 杭州，浙江省肿瘤医院
  • 收稿日期:1900-01-01 修回日期:1900-01-01 出版日期:2010-10-15 发布日期:2010-10-15
  • 通讯作者: 高永良

Tumor Marker for Clinical Application in Ovarian Cancer

GAO Yong-liang   

  1. Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Received:1900-01-01 Revised:1900-01-01 Published:2010-10-15 Online:2010-10-15
  • Contact: GAO Yong-liang

PDF (PC)

4739

摘要： 早期卵巢癌的生存率较高，而晚期者生存率甚低。高敏感度与高特异度的卵巢癌标志物有助于卵巢癌的早期发现，无疑也将提高卵巢癌的生存率。CA125和人类附睾蛋白4（HE4）是卵巢癌诊断与监测最重要的标志物，也是迄今仅有的美国食品药品管理局（FDA）批准作为临床卵巢癌监测的2个肿瘤标志物。利用卵巢癌的肿瘤标志物可以提高卵巢癌筛查效率，鉴别盆腔肿块性质及监测病情，熟悉卵巢癌的肿瘤标志物并合理用于临床，将进一步提高卵巢癌的诊治水平。

关键词: 卵巢肿瘤, 肿瘤标记, 生物学, 抗原, 肿瘤, CA-125抗原, 人类附睾蛋白4

Abstract: High survival rate is seen in the early stage of ovarian cancer, but survival rate is very low in advanced stage. High sensitivity and high specificity ovarian cancer markers help the early detection of ovarian cancer, no doubt will increase the survival rate of ovarian cancer. CA125 and HE4 are the most important markers for ovarian cancer and the only two by the U.S. FDA approval for clinical monitoring ovarian cancer so far. Use of tumor markers can increase ovarian cancer screening efficiency, identify malignant or benign pelvic mass, and monitoring disease status.

Key words: Ovarian neoplasms, Tumor markers, biological, Antigens, neoplasm, CA-125 antigen